Retatrutide vs Semaglutide vs Tirzepatide: Comparing Triple vs Dual vs Single Agonist Peptides in Research

A comparison of retatrutide vs semaglutide vs tirzepatide examines three distinct approaches to metabolic receptor activation: retatrutide targets GIP, GLP-1, and glucagon receptors; tirzepatide targets GIP and GLP-1 receptors; and semaglutide acts through GLP-1 receptors alone. These differences explain much of the current research interest in the triple-agonist class, but they do not provide a clinical ranking or establish that one medicine is appropriate for every patient.

This article will compare the three agents across receptor activity, weight and glucose outcomes, tolerability, regulatory status, and emerging metabolic applications. Doctor Medica supports research-focused professionals across medical fields; those looking to buy retatrutide can reach Doctor Medica’s staff for sourcing guidance.

Key Takeaways

• Retatrutide is an investigational triple-receptor agonist, whereas semaglutide and tirzepatide are available as FDA-approved products.
• Tirzepatide produced greater average weight reduction than semaglutide in a direct 72-week trial. Retatrutide has shown higher numerical results in Lilly’s topline Phase 3 obesity readout, but has not been directly compared with either medicine.
• All three have demonstrated metabolic effects, although the available evidence, approved indications, and long-term regulatory experience differ substantially among them.

About: Doctor Medica is your trusted all-in-one supplier of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like Retatrutide. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Doctor Medica, we prioritize serving you better to improve the patient’s quality of life.

How Do Retatrutide, Semaglutide, and Tirzepatide Differ in Mechanism?

The primary difference lies in the number and combination of receptors each molecule activates.

Comparison Point	Retatrutide	Semaglutide	Tirzepatide
Receptor activity	GIP, GLP-1, and glucagon	GLP-1	GIP and GLP-1
Research class	Triple receptor agonist	Single GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Company	Eli Lilly and Company	Novo Nordisk	Eli Lilly and Company
Current status	Investigational	Approved products available	Approved products available
Obesity brand	No approved brand name	Wegovy®	Zepbound®
Type 2 diabetes brand	None	Ozempic® and Rybelsus®	Mounjaro®

Semaglutide imitates GLP-1 activity, influencing glucose-dependent insulin secretion, appetite regulation, and gastric emptying. Tirzepatide adds GIP receptor activity to GLP-1 receptor agonism. Retatrutide adds a third target, the glucagon receptor, to the GIP and GLP-1 combination. [2]

The difference between retatrutide and tirzepatide is not simply a generational update. Tirzepatide is a dual agonist; retatrutide is an engineered single peptide molecule designed to activate three receptor systems. Retatrutide is also known by its development code LY3437943 and does not currently have an approved commercial brand name. Although it is sometimes informally called “GLP-3,” it is a nickname rather than a standard or approved scientific term. The correct description is a GIP/GLP-1/glucagon triple receptor agonist. [2]

Efficacy Data — What Does Clinical Research Show for Each?

The strongest direct comparative evidence currently exists between tirzepatide and semaglutide. In SURMOUNT-5, adults with obesity but without type 2 diabetes received the maximum tolerated dose of either agent for 72 weeks. Average body weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide, and tirzepatide also produced a greater average reduction in waist circumference. [1]

Retatrutide has not been included in a direct trial against either of the medicines. Its results come from separate studies with different populations, durations, protocols, and statistical approaches.

According to Lilly’s topline Phase 3 obesity readout, participants without diabetes receiving retatrutide experienced average weight reductions of 19.0% at 80 weeks in the 4mg group, 25.9% in the 9mg group, and 28.3% in the 12mg group. [5] A prespecified extension subset of participants with a baseline BMI of at least 35 who completed the 80-week study and tolerated therapy continued through 104 weeks; in that subgroup, the highest-dose group reported an average reduction of 30.3%. [5]

Note: This is an extension subset result, not a primary Phase 3 endpoint.

These numerical results may make retatrutide appear more effective than semaglutide or tirzepatide. The absence of a direct randomized comparison means that differences between studies could partly reflect participant characteristics, study length, escalation design, adherence, or analytical methods. Tirzepatide has demonstrated greater average weight reduction than semaglutide in a direct head-to-head trial [1]; retatrutide has produced higher numerical averages in Lilly’s topline Phase 3 reporting, but superiority over either approved medicine has not been established. [5]

For professionals also reviewing preparation logistics, information on how to reconstitute retatrutide covers research handling only and cannot be used to infer product equivalence, clinical performance, or patient outcomes.

Side Effect Profiles — How Do They Compare?

The three agents show considerable overlap in gastrointestinal tolerability. Across clinical trials, nausea, diarrhea, constipation, and vomiting were commonly reported with each compound, especially during dose-escalation periods.[1][5]

In SURMOUNT-5, gastrointestinal events were the most frequent adverse events with both tirzepatide and semaglutide, and were generally mild to moderate. Neither medicine was free of the GI effects associated with incretin-based treatment. [1]

Lilly’s topline TRIUMPH-1 reporting described the same general pattern with retatrutide. Nausea occurred in 28.6% to 42.4% of participants depending on the research group, diarrhea in 25.2% to 34.1%, constipation in 23.8% to 26.1%, and vomiting in 10.6% to 25.3%. Discontinuation due to adverse events increased across the higher-dose groups. [5] One observation less common in the other agents was dysesthesia, defined as altered or unusual skin sensations, which was reported more frequently with retatrutide than placebo in TRIUMPH-1. However, most events were described as mild to moderate. [5]

The main limitation in comparing these agents is that they are at different stages of regulatory development. Semaglutide has the longest history of post-approval use, while tirzepatide is supported by approved labeling and a growing body of real-world evidence. Retatrutide, by contrast, is still being evaluated in clinical trials and has not completed FDA review. Its safety profile may therefore change as more Phase 3 findings, longer-term follow-up, and regulatory assessments become available.

Is Retatrutide Still in Clinical Trials? Regulatory Status Comparison

Retatrutide remains investigational and has not received FDA approval. It does not have an authorized brand-name formulation and cannot be prescribed for routine clinical use. Eli Lilly continues to evaluate the compound across several research areas, including obesity, type 2 diabetes, osteoarthritis pain, obstructive sleep apnea, cardiovascular and kidney outcomes, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease.[2]

Semaglutide and tirzepatide already have FDA-approved products. Wegovy® is approved for long-term weight management and also has indications for cardiovascular risk reduction and metabolic dysfunction-associated steatohepatitis; other semaglutide products are approved for type 2 diabetes. [3] Zepbound® is approved for long-term weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, while Mounjaro® is approved for type 2 diabetes. [4] Retatrutide has no approved indication; its potential uses remain under clinical investigation. [2]

This distinction matters when comparing weight-loss medications. Promising topline Phase 3 data do not provide the same regulatory assurance as an approved prescribing label.

Metabolic and Liver Disease Applications — What Does Research Suggest?

The three compounds are also being evaluated for effects beyond body weight, though the level of evidence and regulatory standing differ considerably.

Semaglutide currently holds the strongest regulatory position in liver disease. In August 2025, the FDA granted accelerated approval to Wegovy® for adults with metabolic dysfunction-associated steatohepatitis and moderate-to-advanced fibrosis without cirrhosis.[3] Tirzepatide has also shown encouraging Phase 2 findings in people with MASH and fibrosis, including MASH resolution without worsening fibrosis, but it does not have an FDA-approved indication for the condition.

Retatrutide remains earlier in development. A relatively small Phase 2a substudy in metabolic dysfunction-associated steatotic liver disease reported substantial reductions in liver fat at higher doses, together with changes in body weight, abdominal fat, and metabolic markers.[6] These findings support further research but do not represent an approved indication.

Research has also expanded into obesity-related conditions beyond liver disease. In a knee osteoarthritis cohort from TRIUMPH-1, WOMAC pain scores decreased by as much as 73.1% from baseline.[5] Although this suggests a possible effect on osteoarthritis-related pain, retatrutide is not approved as an osteoarthritis treatment.

For type 2 diabetes, semaglutide and tirzepatide are supported by extensive clinical evidence and approved labeling. Retatrutide has likewise produced improvements in glucose-related outcomes, but these findings remain part of an investigational development program. Its added glucagon receptor activity is being studied for potential effects on energy expenditure, lipid metabolism, and hepatic fat beyond those associated with GLP-1 and GIP activity alone.[2]

Retatrutide vs Semaglutide vs Tirzepatide — Which Does Research Suggest Is More Effective?

Which agent appears more effective depends on the outcome being assessed and the quality of the available comparative evidence. For retatrutide vs semaglutide and retatrutide vs tirzepatide, no randomized head-to-head trial has yet been reported. Retatrutide’s topline Phase 3 weight-loss figures are numerically higher than those in semaglutide and tirzepatide studies, but differences in study design, duration, participant characteristics, and analytical methods mean these results cannot be treated as equivalent to a direct comparison. [1][5]

The comparison between tirzepatide and semaglutide is more straightforward because the two drugs have been studied head-to-head. In SURMOUNT-5, tirzepatide produced significantly greater average reductions in body weight and waist circumference than semaglutide.[1]

Even so, the available evidence does not support a simple overall ranking of all three agents. Weight loss is only one part of the comparison. Regulatory status, approved indications, safety data, tolerability, comorbidities, monitoring needs, access, and long-term clinical experience also matter.

Semaglutide has the broadest range of approvals and the longest regulatory history. Tirzepatide has outperformed semaglutide in a direct trial and is approved for weight management and obstructive sleep apnea. Retatrutide has reported the largest numerical average weight reductions in Phase 3 topline findings, but it remains investigational. A complete, peer-reviewed assessment of its benefits and risks is still pending.

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394

[2] Eli Lilly and Company. What to Know About Retatrutide. Published June 7, 2026. https://www.lilly.com/news/stories/what-to-know-about-retatrutide

[3] U.S. Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as MASH. Updated August 15, 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash

[4] U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. Published December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

[5] Eli Lilly and Company. Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial. Published May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss

[6]Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.